@article {Bi2020.11.04.20225573, author = {Qifang Bi and Justin Lessler and Isabella Eckerle and Stephen A Lauer and Laurent Kaiser and Nicolas Vuilleumier and Derek AT Cummings and Antoine Flahault and Dusan Petrovic and Idris Guessous and Silvia Stringhini and Andrew S. Azman and for the SEROCoV-POP Study Group}, title = {Household Transmission of SARS-CoV-2: Insights from a Population-based Serological Survey}, elocation-id = {2020.11.04.20225573}, year = {2021}, doi = {10.1101/2020.11.04.20225573}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Background Knowing the transmissibility of asymptomatic infections and risk of infection from household- and community-exposures is critical to SARS-CoV-2 control. Limited previous evidence is based primarily on virologic testing, which disproportionately misses mild and asymptomatic infections. Serologic measures are more likely to capture all previously infected individuals.Objective Estimate the risk of SARS-CoV-2 infection from household and community exposures, and identify key risk factors for transmission and infection.Design Cross-sectional household serosurvey and transmission model.Setting Geneva, SwitzerlandParticipants 4,524 household members >=5 years from 2,267 households enrolled April-June 2020.Measurements Past SARS-CoV-2 infection confirmed through IgG ELISA. Chain-binomial models based on the number of infections within households used to estimate the cumulative extra-household infection risk and infection risk from exposure to an infected household member by demographics and infector{\textquoteright}s symptoms.Results The chance of being infected by a SARS-CoV-2 infected household member was 17.3\% (95\%CrI,13.7-21.7\%) compared to a cumulative extra-household infection risk of 5.1\% (95\%CrI,4.5-5.8\%). Infection risk from an infected household member increased with age, with 5-9 year olds having 0.4 times (95\%CrI, 0.07-1.4) the odds of infection, and >=65 years olds having 2.7 (95\%CrI,0.88-7.4) times the odds of infection of 20-49 year olds. Working-age adults had the highest extra-household infection risk. Seropositive asymptomatic household members had 69.6\% lower odds (95\%CrI,33.7-88.1\%) of infecting another household member compared to those reporting symptoms, accounting for 14.7\% (95\%CrI,6.3-23.2\%) of all household infections.Limitations Self-reported symptoms, small number of seropositive kids and imperfect serologic tests.Conclusion The risk of infection from exposure to a single infected household member was more than three-times that of extra-household exposures over the first pandemic wave. Young children had a lower risk of infection from household members. Asymptomatic infections are far less likely to transmit than symptomatic ones but do cause infections.Funding Source Swiss Federal Office of Public Health, Swiss School of Public Health (Corona Immunitas research program), Fondation de Bienfaisance du Groupe Pictet, Fondation Ancrage, Fondation Priv{\'e}e des H{\^o}pitaux Universitaires de Gen{\`e}ve, and Center for Emerging Viral Diseases.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study grants from Swiss Federal Office of Public Health, Swiss School of Public Health (Corona Immunitas research program), Fondation de Bienfaisance du Groupe Pictet, Fondation Ancrage, Fondation Privee des Hopitaux Universitaires de Geneve, and Center for Emerging Viral Diseases. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Cantonal Research Ethics Commission of Geneva, Switzerland (CER16-363). All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesCode to reproduce analyses will be posted on github (https://github.com/HopkinsIDD/serocovpop-households) and data will be made available upon request to the corresponding author. https://github.com/HopkinsIDD/serocovpop-households}, URL = {https://www.medrxiv.org/content/early/2021/01/16/2020.11.04.20225573}, eprint = {https://www.medrxiv.org/content/early/2021/01/16/2020.11.04.20225573.full.pdf}, journal = {medRxiv} }